Biophytis S.A. (BPTSY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biophytis S.A. (BPTSY) has a cash flow conversion efficiency ratio of 0.000x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.98K) by net assets ($-6.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biophytis S.A. - Cash Flow Conversion Efficiency Trend (2013–2023)
This chart illustrates how Biophytis S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read BPTSY current and long-term liabilities for a breakdown of total debt and financial obligations.
Biophytis S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biophytis S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BGT Corporation Public Company Limited
BK:BGT
|
0.114x |
|
Austin Metals Ltd
AU:AYT
|
-0.024x |
|
Zelira Therapeutics Ltd
AU:ZLD
|
0.530x |
|
CQS New City High Yield Fund
LSE:NCYF
|
-0.028x |
|
Leveljump Healthcare Corp
V:JUMP
|
0.065x |
|
Crown Energy AB (publ)
F:CWE
|
-0.020x |
|
Henderson International Income Trust PLC
LSE:HINT
|
0.024x |
|
Anagenics Ltd
AU:AN1
|
-0.286x |
Annual Cash Flow Conversion Efficiency for Biophytis S.A. (2013–2023)
The table below shows the annual cash flow conversion efficiency of Biophytis S.A. from 2013 to 2023. For the full company profile with market capitalisation and key ratios, see market cap of Biophytis S.A..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-3.89 Million | $-12.87 Million | 3.310x | -66.69% |
| 2022-12-31 | $-1.91 Million | $-18.99 Million | 9.936x | +338.23% |
| 2021-12-31 | $5.71 Million | $-23.80 Million | -4.171x | -188.88% |
| 2020-12-31 | $6.83 Million | $-9.86 Million | -1.444x | -171.15% |
| 2019-12-31 | $-7.53 Million | $-15.27 Million | 2.029x | +217.92% |
| 2018-12-31 | $7.01 Million | $-12.06 Million | -1.721x | -317.79% |
| 2017-12-31 | $21.19 Million | $-8.73 Million | -0.412x | +71.94% |
| 2016-12-31 | $4.52 Million | $-6.63 Million | -1.468x | -433.55% |
| 2015-12-31 | $11.67 Million | $-3.21 Million | -0.275x | -147.13% |
| 2014-12-31 | $-1.13 Million | $-658.89K | 0.584x | -70.26% |
| 2013-12-31 | $-409.32K | $-803.29K | 1.962x | -- |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, … Read more